Juan Carlos Cardet, AAAAI 2022: Reducing Severe Asthma Exacerbations in the PREPARE Study

We were delighted to talk with Dr. Juan Carlos Cardet (University of South Florida, Tampa, FL, USA) to discuss the PREPARE study, testing a Patient-Activated Reliever-Triggered Inhaled Corticosteroid (ICS) Strategy (PARTICS) in African American/Black and Hispanic/Latinx patients.

The abstract ‘Successfully Reducing Severe Asthma Exacerbations and Improving Asthma Control in a Pragmatic Study in African American/Black (AA/B) and Hispanic/Latinx (H/L) Patients with Moderate-Severe Asthma (PREPARE).’ was presented at AAAAI 2022, 25-28 February.

Questions

1. Could you tell us a little about the health burden of asthma in African American/Black and Hispanic/Latinx patients? (0:11)
2. What was the rationale for and design of the study you are presenting? (1:25)
3. What were the outcome measures of the study and how well were they achieved? (2:43) 
4. What will be the impact of these findings on future clinical practice? (9:46)
5. What questions remain unanswered and what future studies are planned? (12:00)

Disclosures: Juan Carlos Cardet discloses receiving grant/ research support from NIH/NIAID, ALA/AAAAI; has served on advisory boards for GSK, Genentech and AstraZeneca; and has received honoraria from GSK, Genentech and AstraZeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. 

Filmed in coverage of the AAAAI annual meeting 2022.